You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Express Scripts
Mallinckrodt
Merck
Baxter

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

IMITREX STATDOSE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Imitrex Statdose patents expire, and what generic alternatives are available?

Imitrex Statdose is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in IMITREX STATDOSE is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

US ANDA Litigation and Generic Entry Outlook for Imitrex Statdose

A generic version of IMITREX STATDOSE was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.

  Start Trial

Drug patent expirations by year for IMITREX STATDOSE
Drug Prices for IMITREX STATDOSE

See drug prices for IMITREX STATDOSE

Recent Clinical Trials for IMITREX STATDOSE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GlaxoSmithKlinePhase 1
GlaxoSmithKlinePhase 4
Diamond Headache ClinicPhase 4

See all IMITREX STATDOSE clinical trials

US Patents and Regulatory Information for IMITREX STATDOSE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-002 Feb 1, 2006 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-003 Dec 23, 1996 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for IMITREX STATDOSE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-002 Feb 1, 2006   Start Trial   Start Trial
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-003 Dec 23, 1996   Start Trial   Start Trial
Glaxosmithkline IMITREX STATDOSE sumatriptan succinate INJECTABLE;SUBCUTANEOUS 020080-003 Dec 23, 1996   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Baxter
McKinsey
Merck
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.